Provide a rationale supported by research to increase the study's patient enrollment: CDSCO advises Eli Lilly on galcanezumab.

Published Date: 04 Sep 2023

New Delhi: In response to the proposal presented by the drug major Eli Lilly for the protocol amendment of the monoclonal antibody Galcanezumab, the.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot